TY - JOUR
T1 - Pharmaceutical and therapeutic equivalence study of the generic medicine containing loxoprofen sodium
AU - Kaneshige, Susumu
AU - Koyanagi, Satoru
AU - Kobayashi, Mami
AU - Ohdo, Shigehiro
AU - Matsunaga, Naoya
AU - Kamimura, Hidetoshi
PY - 2012
Y1 - 2012
N2 - Objectives: The use of generic medicines is generally recommended for reducing medical costs. However, many doctors and pharmacists do not trust the quality, efficacy and safety of some generic medicines. Loxonin® containing loxoprofen sodium is widely used as an antipyretics analgesic, and Lobu® is the generic form of Loxonin® The pharmaceutical and therapeutic equivalence of Lobu® was compared to Loxonin® Methods: The dissolution rate of loxoprofen sodium from Lobu® was compared to that of Loxonin®. In addition, clinical data of the patients treated with Lobu® in Fukuoka Memorial Hospital was compared to those treated with Loxonin® in Fukuoka University Chikushi Hospital. The number of patients treated with Lobu® and Loxonin® was 76 and 79, and the mean age was 45.8 years old and 47.5 years old, respectively. Results: Lobu® did not meet the standard of the dissolution test of loxoprofen sodium at a pH of 1.2. However, the analgesic effect of Lobu® on patients undergone orthopedic surgery was equal to that of Loxonin®. In addition, severe hematopoietic injury, hepatic dysfunction, or renal dysfunction were not observed during Lobu® treatment. Conclusions: Although Lobu® is not 100% pharmaceutically equivalent to Loxonin® the efficacy and safety are considered to be equivalent to Loxonin®.
AB - Objectives: The use of generic medicines is generally recommended for reducing medical costs. However, many doctors and pharmacists do not trust the quality, efficacy and safety of some generic medicines. Loxonin® containing loxoprofen sodium is widely used as an antipyretics analgesic, and Lobu® is the generic form of Loxonin® The pharmaceutical and therapeutic equivalence of Lobu® was compared to Loxonin® Methods: The dissolution rate of loxoprofen sodium from Lobu® was compared to that of Loxonin®. In addition, clinical data of the patients treated with Lobu® in Fukuoka Memorial Hospital was compared to those treated with Loxonin® in Fukuoka University Chikushi Hospital. The number of patients treated with Lobu® and Loxonin® was 76 and 79, and the mean age was 45.8 years old and 47.5 years old, respectively. Results: Lobu® did not meet the standard of the dissolution test of loxoprofen sodium at a pH of 1.2. However, the analgesic effect of Lobu® on patients undergone orthopedic surgery was equal to that of Loxonin®. In addition, severe hematopoietic injury, hepatic dysfunction, or renal dysfunction were not observed during Lobu® treatment. Conclusions: Although Lobu® is not 100% pharmaceutically equivalent to Loxonin® the efficacy and safety are considered to be equivalent to Loxonin®.
UR - http://www.scopus.com/inward/record.url?scp=84873810717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873810717&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84873810717
SN - 0386-3603
VL - 40
SP - 1081
EP - 1088
JO - Japanese Pharmacology and Therapeutics
JF - Japanese Pharmacology and Therapeutics
IS - 12
ER -